文献速递免疫规划慢病防控与筛查卫生政策与健康促进

澳大利亚维多利亚州新冠疫苗相关心肌炎的长期随访与结局:一项临床监测研究

Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
PubMed 文献 · Vaccine · 2023-12-27

该研究通过维多利亚州疫苗安全监测服务(SAEFVIC)对新冠疫苗接种后确诊心肌炎(Brighton协作标准1-3级)病例进行1、3、6个月问卷调查,分析2021年2月22日至2022年9月30日的回复。182名合格参与者完成至少1次调查,6个月时54.8%报告持续症状,女性持续症状显著多于男性,男性症状缓解率更高但初始峰值肌钙蛋白和心脏影像异常更显著。

要点

  • 6个月随访时54.8%(n=74)的问卷报告仍有持续症状。
  • 6个月时男性症状缓解率51.9% vs 女性22.6%(p=0.002)。
  • 男性初始峰值肌钙蛋白更高且初始心脏影像异常更显著。

核心结论

  • 新冠疫苗相关心肌炎患者中相当比例在发病后6个月仍有持续症状。
  • 男性患者虽初始平均峰值肌钙蛋白显著更高,但更可能报告更早和更完全的症状恢复。
  • 女性与男性表型表现的差异需进一步研究,且需要更长期随访数据。

研究设计与样本

  • 基于澳大利亚维多利亚州疫苗安全监测服务(SAEFVIC)的临床监测研究。
  • 对确诊心肌炎病例(Brighton协作标准1-3级)在症状 onset 后1、3、6个月进行问卷调查。
  • 分析2021年2月22日至2022年9月30日收到的回复。
  • 87.5%(N=182)的合格参与者完成至少1次调查,共分析377份报告。

主要发现

  • 完成报告中76.9%来自男性患者,患者中位年龄21岁(IQR:16至32)。
  • 6个月时54.8%(n=74)的问卷报告持续症状。
  • 所有随访时间点女性持续症状的可能性显著更高。
  • 6个月时男性受访者症状缓解率51.9% vs 女性22.6%(p=0.002)。
  • 女性更可能继续用药并持续运动限制,男性初始峰值肌钙蛋白更高且初始心脏影像异常更显著。

局限性

  • 原文指出关于较长期结局的信息仍有限。
  • 原文指出女性与男性表型表现的差异需进一步研究。
  • 原文指出需要更长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocarditis and myopericarditis are well described adverse events of special interest (AESI) following COVID-19 vaccinations. Although reports are reassuring regarding initial clinical outcomes, information about longer term outcomes remains limited. We aimed to further this knowledge and report outcomes to 6 months post diagnosis from a single population cohort. METHODS: Reports of myocarditis following COVID-19 vaccination were followed up by SAEFVIC (Surveillance of Adverse Events Following Vaccination in the Community), the state-wide vaccine safety service for Victoria, Australia. Confirmed myocarditis cases (Brighton Collaboration Criteria levels 1-3) were followed up via surveys at 1, 3 and 6 months post symptom onset. Responses received between 22 February 2021 and 30 September 2022 were analysed. RESULTS: 87.5 % (N = 182) of eligible participants completed at least 1 survey report. 377 reports were analysed. 76.9 % of completed reports were from male patients. The median age of patients was 21 years [IQR: 16 to 32]. 54.8 % (n = 74) of survey reports at 6 months, reported ongoing symptoms. At all follow-up time points, females were significantly more likely to have ongoing symptoms. At 6 months, 51.9 % of male respondents reported symptom resolution compared to 22.6 % of female patients (p = 0.002). Females were also more likely to continue medication and have ongoing exercise restrictions. However, males were significantly more likely to have higher initial peak troponin results and abnormal initial cardiac imaging investigations. CONCLUSIONS: There appears to be a significant proportion of patients who experience ongoing symptoms to 6 months post onset amongst patients that experience these AESI. Male patients were more likely to report earlier and more complete symptom recovery, despite significantly higher average initial peak troponin. This difference in phenotypic presentation in females compared to males warrants further investigation and there is a need for longer term follow up data.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shenton P, Schrader S, Smith J, et al. Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study. Vaccine. 2023. PMID: 38154991. doi:10.1016/j.vaccine.2023.12.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。